CDK7 antibody | MO-1.1

100% Secure

No associated image currently available

Mouse anti Human CDK7

Product Type: Monoclonal Antibody
Clone: MO-1.1
Isotype: IgG2b

Product Code	Applications	Datasheet	MSDS	Pack Size	List Price	Quantity
MCA1993	C IP WB			0.1 mg

Mouse anti Human Cdk7 antibody, clone MO-1.1 recognizes human Cyclin-dependent kinase 7, also known as 39 kDa protein kinase, Cell division protein kinase 7, Serine/threonine-protein kinase 1 and TFIIH basal transcription factor complex kinase subunit. Cdk7 is a 346 amino acid member of the CDC2/CDKX subfamily of serine/threonine family of protein kinases. Cdk7, as part of the CAK complex is involved with the transcription factor TFIIH and is thought to be involved in the control of cell cycle progression, DNA repair and RNA polymerase II (pol II) transcription.

Cdk7 demonstrates ubiquitous muclear expression in normal tissues and is expressed in cancer tissues (Bartkova et al. 1996).

Product Details

Target Species

Human

Product Form

Purified IgG - liquid

Preparation

Purified IgG prepared by affinity chromatography on Protein A/G

Buffer Solution

Phosphate buffered saline

Preservative Stabilisers

0.08%

Sodium Azide

Immunogen

221 amino acid recombinant fragment of Cdk7 C terminus

Approx. Protein Concentrations

IgG concentration 1.0mg/ml

Fusion Partners

Spleen cells derived from immunized Balb/c mice were fused with cells from the NS-2 mouse myeloma.

Storage Information

Storage: Store at +4^oC or at -20^oC if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee: 18 months from date of despatch.

More Information

UniProt: P50613 Related reagents
Entrez Gene: CDK7 Related reagents
GO Terms: GO:0000079 regulation of cyclin-dependent protein kinase activity; GO:0000080 G1 phase of mitotic cell cycle; GO:0000082 G1/S transition of mitotic cell cycle; GO:0000084 S phase of mitotic cell cycle; GO:0000086 G2/M transition of mitotic cell cycle; GO:0000718 nucleotide-excision repair, DNA damage removal; GO:0003713 transcription coactivator activity; GO:0005739 mitochondrion; GO:0004693 cyclin-dependent protein kinase activity; GO:0005524 ATP binding; GO:0005675 holo TFIIH complex; GO:0006283 transcription-coupled nucleotide-excision repair; GO:0006361 transcription initiation from RNA polymerase I promoter; GO:0006362 transcription elongation from RNA polymerase I promoter; GO:0006363 termination of RNA polymerase I transcription; GO:0006367 transcription initiation from RNA polymerase II promoter; GO:0006368 transcription elongation from RNA polymerase II promoter; GO:0006370 mRNA capping; GO:0006468 protein phosphorylation; GO:0008022 protein C-terminus binding; GO:0008094 DNA-dependent ATPase activity; GO:0008283 cell proliferation; GO:0008353 RNA polymerase II carboxy-terminal domain kinase activity; GO:0016032 viral reproduction; GO:0030521 androgen receptor signaling pathway; GO:0045944 positive regulation of transcription from RNA polymerase II promoter; GO:0050434 positive regulation of viral transcription; GO:0050681 androgen receptor binding; GO:0051301 cell division
Regulatory: For research purposes only

Applications of CDK7 antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.

Application Name	Min Dilution	Max Dilution
Immunohistology - Frozen
Immunoprecipitation
Western Blotting	1ug/ml	10ug/ml

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

Histology Positive Control Tissue: HeLa cells fixed with acetone/methanol

Secondary Antibodies Available

Description	Product Code	Pack Size	Applications
Human anti Mouse IgG2b:FITC	HCA038F	0.1 mg	F
Goat anti Mouse IgG (H/L):Alk. Phos. (Multi Species Adsorbed)	STAR117A	0.5 mg	E WB
Goat anti Mouse IgG (H/L):DyLight®488 (Multi Species Adsorbed)	STAR117D488GA	0.1 mg	F IF
Goat anti Mouse IgG (H/L):DyLight®680 (Multi Species Adsorbed)	STAR117D680GA	0.1 mg	F WB
Goat anti Mouse IgG (H/L):DyLight®800 (Multi Species Adsorbed)	STAR117D800GA	0.1 mg	F IF WB
Goat anti Mouse IgG (H/L):FITC (Multi Species Adsorbed)	STAR117F	0.5 mg	F
Goat anti Mouse IgG (H/L):HRP (Multi Species Adsorbed)	STAR117P	0.5 mg	E WB
Goat anti Mouse IgG (Fc):FITC	STAR120F	1 mg	C F
Goat anti Mouse IgG (Fc):HRP	STAR120P	1 mg	E WB
Rabbit F(ab')2 anti Mouse IgG:RPE	STAR12A	1 ml	F
Rabbit F(ab')2 anti Mouse IgG:HRP (Human Adsorbed)	STAR13B	1 mg	C E P RE WB
Goat anti Mouse IgG:FITC (Rat Adsorbed)	STAR70	0.5 mg	F
Goat anti Mouse IgG:RPE (Rat Adsorbed)	STAR76	1 ml	F
Goat anti Mouse IgG:HRP (Rat Adsorbed)	STAR77	0.5 mg	C E P
Goat anti Mouse IgG/A/M:Alk. Phos.	STAR87A	1 mg	C E WB
Goat anti Mouse IgG/A/M:HRP (Human Adsorbed)	STAR87P	1 mg	E
Rabbit F(ab')2 anti Mouse IgG:Dylight®800	STAR8D800GA	0.1 mg	F IF WB
Rabbit F(ab')2 anti Mouse IgG:FITC	STAR9B	1 mg	F

Application Based External Images

Western Blotting

Product Specific References

References for CDK7 antibody

Tassan, J.P. et al. (1994) Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase).
J Cell Biol. 127 (2): 467-78.
Syljuåsen, R.G. et al. (2006) Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases.
Cancer Res. 66: 10253-7.
Aagaard, L. et al. (1995) Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines.
Int J Cancer. 61 (1): 115-20.
Falck, J. et al. (2001) Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway.
Oncogene. 20: 5503-10.